KRYS

Krystal Biotech, Inc.

$368.60 -6.08 (-1.62%) At close · Jul 7

Market Cap

$10.87B

29,479,756

Equibles Rating blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Strong Buy Momentum Very Strong Sentiment Bullish Fundamentals Excellent Quant / Vol Moderate

Market backdrop VIX 16.1 · calm Equity put/call 0.69

Technical

price trend

Strong Buy

50 / 200-day cross No cross

Price vs 200-day avg +44%

above

Price vs 50-day avg +17%

above

RSI (14) 68

neutral

MACD trend Positive

52-week position 94%

near high

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Strong

1-month return +22%

trailing

6-month return +35%

trailing

YTD return +50%

this year

Relative strength +28%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $315 › 200d $256 — 50d above 200d

Institutional flow Accumulating

9 of 370 funds reported for Jun 30 · net +40.7K sh shares · +4 new

Insider flow Distributing

Net -$15.6M over 90 days · 100% sells

Short interest Falling

10.65% of float · ▼ -0.3% MoM · 10.9 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

370 holders — near 3-yr high, broad support

Squeeze score 71

high risk · 0–100

Fundamentals

Excellent

Revenue growth +34%

Y/Y

EPS growth +128%

Y/Y

Free cash flow $188.9M

Valuation P/E 49.3

rich

Balance sheet $492.1M

net cash

Quant / Vol

risk profile

Moderate

Volatility 39%

annualized · 1-yr

Max drawdown −16%

past year

ATR 3.4%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Up next

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed May 4, 2026

AI Brief

TL;DR.

Bullish

Bearish

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Technicals

trend & momentum for long-term holders Strong Buy

0 · 3 · 4

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+44% Bullish

Price vs 50-day avg

+17% Bullish

RSI (14)

68 Neutral

MACD trend

Positive Bullish

52-week position

94% Bullish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $315 › 200d $256 — 50d above 200d

Institutional flow Accumulating

9 of 370 funds reported for Jun 30 · net +40.7K sh shares · +4 new

Insider flow Distributing

Net -$15.6M over 90 days · 100% sells

Short interest Falling

10.65% of float · ▼ -0.3% MoM · 10.9 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

370 holders — near 3-yr high, broad support

Price context

position in its 52-week range

52-wk low $131 Now $369 · 94% 52-wk high $383

vs 200-day avg +44% vs 50-day avg +17%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from its earnings releases, calls, and filings

Metric	Latest	Period	YoY
cumulative net VYJUVEK revenue since launch	$846M	since launch call	—
DDEB patients prescribed VYJUVEK across Germany, Japan and France	140	Q1 2026 call	—
Europe plus Japan net revenue	$28.9M	Q1 2026 call	—
new prescribers in Q1	60	Q1 2026 call	—
patients enrolled in KB803 registrational study	16	Q1 2026 call	—
reimbursement approvals for DDEB patients	695	Q1 2026 call	—
U.S. net VYJUVEK revenues	$87.5M	Q1 2026 call	—
unique prescribers since launch	570	since launch call	—
VYJUVEK net revenue sequential growth	9%	Q1 2026 vs Q4 2025 call	—
Gross margin	94%	fourth quarter and full year of 2025	—

Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
KRYS Krystal Biotech, Inc. this stock	$10.87B	+49.5%	+33.9%	49.3	10.6%
ONC BeOne Medicines Ltd.	$446.53B	+1.7%	+22179.2%	908.7	0.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$132.55B	+15.2%	+46.2%	31.0	1.8%
REGN Regeneron Pharmaceuticals, Inc.	$70.90B	-12.3%	+20.8%	16.5	3.2%
ARGX Argenx SE	$57.49B	+9.4%	—	—	2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

374

% held: 92.9%
Reported: 9 of 370
Top holder: FMR LLC

Held Float

View

Held by Funds

Fund positions

343

View

Short & Settlement

Short Interest Falling

Shares short

3.1M

Days to cover: 10.9d
Change: -9.6K sh

View

Short Volume

Short vol %

78%

As of: Jul 7, 2026

Short Total

View

Fails to Deliver

FTD shares

Value: $1.3K
As of: Jun 12, 2026

View

Off-Exchange

Off-exchange %

49.1%

Week of: May 4, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$15.6M

Buyers / Sellers: 0 / 3

Buyers Sellers

View

Congressional Trades Buy

Member

Christopher L. Jacobs

Amount: $1.0K–$15.0K
Traded: Dec 12, 2022

View

Financials

Revenue (FY)

$389.1M

Net income (FY): $204.8M
EPS diluted: $6.84

View

Filings

SEC Filings

Latest

8-K

Filed: May 20, 2026
This year: 8

View

Proposed Sales

Value

$347.3K

Shares: 1.0K
Filed: Jun 25, 2026

View

Earnings & Events

Earnings Calls

Last call

May 13, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
KRYS	-2.5%	+22.5%	+35.5%	-0.8%	+49.5%
SPY	+0.9%	+1.4%	+7.6%	+0.1%	+9.7%
vs SPY	-3.4%	+21.1%	+27.9%	-1.0%	+39.9%

Key facts CIK 1711279 CUSIP 501147102 13F (30d) 12 filings 11 filers Visit website Investor relations

KRYS

Price & Indicators

Technicals

Key metrics

Versus peers

At a glance

Performance